Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Banco Bilbao Vizcaya Argentaria SA (BBVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Banco Bilbao Vizcaya Argentaria SA — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.06B), while Banco Bilbao Vizcaya Argentaria SA trades at $28.62 (market cap $157.51B). The key difference: Banco Bilbao Vizcaya Argentaria SA is far larger — about 31.1× ACADIA Pharmaceuticals Inc.'s market cap, and Banco Bilbao Vizcaya Argentaria SA pays a 3.8% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | BBVA | |
|---|---|---|
Market Cap | $5.06B | $157.51B |
Sector | Health | Financials |
52-Week High | $29.39 | $28.36 |
52-Week Low | $20.06 | $17.96 |
Enterprise Value | $4.18B | — |
Dividend Yield | — | 3.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.21, up 2.67% today, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat expectations with EPS of $0.18 versus $0.07 expected, driven by robust Daybue and Nuplazid sales, leading to a raised 2026 revenue outlook. The stock shows high profitability with a net margin of 33.42% and ROE of 35.74%, though valuation metrics like EV/EBITDA of 42.2 indicate premium pricing.
The outlook is positive with 70% analyst buy ratings and a $33 consensus target, but risks include reliance on key drugs and Phase 2 trial results for remlifanserin due by October 2026. Cash flow volatility from heavy investing outlays in 2025 warrants monitoring, but operational strength supports growth potential.
BBVA trades at $28.35, up 0.75% today, with a bullish technical signal from moving averages and strong fundamental performance. The bank reported Q2 2026 net profit growth of 11.4% year-over-year, driven by Mexico operations, and announced a $2.3 billion buyback. Revenue reached $39.42 billion in 2025, with net income margin at 26.13% and ROE of 18.5%, though cash flow was negative in 2024.
Outlook is positive with raised profitability guidance (ROTE ~21%) and analyst consensus leaning buy (54%), but risks include a Spanish court trial for spying allegations and antitrust probes. The stock offers value with a P/E of 12.98, yet investors should monitor legal overhangs and macroeconomic volatility in core markets like Spain and Mexico.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Banco Bilbao Vizcaya Argentaria SA
Despite its Spanish origins, BBVA generates three quarters of its profits in emerging markets, especially Mexico that contributes nearly half of BBVA's net profit. BBVA is overwhelmingly a retail and commercial bank with corporate and investment banking forming a smaller part of the overall business.
Read more on BBVA →
